Recently, the China Drug Administration passed the priority review and approval procedure to conditionally approve the marketing of the Class 1 innovative drug, aledomide hydrochloride capsules declared by Bristol-Myers Squibb Pharma EEIG. This drug, in combination with daretuumab and dexamethasone, is suitable for treating adult patients with multiple myeloma who have received at least first-line treatment in the past. The launch of this drug provides patients with new treatment options.

Recently, the China Drug Administration passed the priority review and approval procedure to conditionally approve the marketing of the Class 1 innovative drug, aledomide hydrochloride capsules declared by Bristol-Myers Squibb Pharma EEIG. This drug, in combination with daretuumab and dexamethasone, is suitable for treating adult patients with multiple myeloma who have received at least first-line treatment in the past. The launch of this drug provides patients with new treatment options.